Skip to main content

Advertisement

SpringerLink
Log in

Targeting the Epidermal Growth Factor Receptor in High-Grade Astrocytomas

  • Central Nervous System Malignancies
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

High-grade astrocytomas, including glioblastoma multiforme (GBM) and anaplastic astrocytoma (AA), are the most common and aggressive primary malignant brain tumors in adults. Despite improvements in survival with the addition of temozolomide to radiation in the adjuvant setting, the prognosis of patients affected by these tumors remains relatively poor. One approach to improve outcomes in these patients is to target the epidermal growth factor receptor (EGFR). EGFR-targeted therapy is a rational approach since EGFR overexpression and mutant EGFRvIII expression occur in approximately 50% of patients with GBM. Unfortunately, monotherapy with anti-EGFR agents in malignant gliomas has not provided the dramatic results sometimes seen with other targeted therapies, such as imatinib in chronic myelogenous leukemia. Anti-EGFR agents currently being studied in malignant gliomas include the tyrosine kinase inhibitors (TKI), monoclonal antibodies (MAb), and anti-EGFR vaccines. Of all these agents, the tyrosine kinase inhibitors—which include erlotinib and gefitinib—have been the most extensively tested in clinical trials. Retrospective analyses have highlighted co-expression of EGFRvIII and wild-type PTEN (phosphatase and tensin homologue deleted in chromosome 10) as a significant predictor of EGFR TKI response in patients with GBM. As the EGFR signaling pathway is exceptionally complex, newer approaches targeting multiple points in the pathway are being developed to improve treatment efficacy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, has been highlighted as: •Of importance ••Of major importance

  1. Jemal A, Siegel R, Ward E, et al.: Cancer Statistics, 2007. CA Cancer J Clin 2007, 57:43

    Article  PubMed  Google Scholar 

  2. Levin VA, Leibel SA, Gutin PH: Neoplasms of the central nervous system. In Cancer: Principles and Practice of Oncology, 6th Edition Edited by DeVita VT Jr, Hellman S, Rosenberg SA. Philadelphia: Lippincott Williams & Wilkins; 2001:2100–2160

    Google Scholar 

  3. •Stupp R, Mason WP, van den Bent MJ, et al.: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352:987–996

    Article  PubMed  CAS  Google Scholar 

Seminal study for current standard of care treatment in GBM

  1. Hegi ME, Diserens AC, Gorlia T, et al.: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005, 352:997–1003

    Article  PubMed  CAS  Google Scholar 

  2. Nieder C, Adam M, Molls M, Grosu AL: Therapeutic options for recurrent high-grade glioma in adult patients: recent advances. Crit Rev Oncol Hematol 2006, 60:181–193

    Article  PubMed  Google Scholar 

  3. Mendelsohn J, Baselga J: The EGF receptor family as targets for cancer therapy. Oncogene 2000, 56:6550–6565

    Article  CAS  Google Scholar 

  4. Frederick L, Wang XY, Eley G, James CD: Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res 2000, 60: 1383–1387

    PubMed  CAS  Google Scholar 

  5. Shinojima N, Tada K, Shiraishi S, et al.: Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res 2003, 63:6962–6970

    PubMed  CAS  Google Scholar 

  6. Guillamo JS, Leuraud P, de Bouard S, et al.: Anti-proliferative and anti-invasive EGFR amplification-dependent and anti-angiogenic EGFR-independent activity of ZD1839 (‹Iressa’) tyrosine kinase inhibitor on human glioblastomas [abstract]. Proc Am Assoc Cancer Res 2003, 44: 1009

    Google Scholar 

  7. Moyer JD, Barbacci EG, Iwata KK, et al.: Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 1997, 57:4838–4848

    PubMed  CAS  Google Scholar 

  8. Stea B, Falsey R, Kislin K, et al.: Time and dose-dependent radiosensitization of the glioblastoma multiforme U251 cells by the EGF receptor tyrosine kinase inhibitor ZD1839 (‹Iressa’). Cancer Lett 2003, 202:43–51

    Article  PubMed  CAS  Google Scholar 

  9. Carlson BL, Schroeder MA, Mladek AC, et al.: Radiosensitization by OSI-774 of serially transplantable human GBM xenografts [abstract]. Proc Soc Neuro-Oncol 2003, 321: MO-01

    Google Scholar 

  10. Iwata KK, Provoncha K, Gibson N, et al.: Inhibition of mutant EGFRvIII-transformed cells by tyrosine kinase inhibitor OSI-774 (Tarceva) [abstract]. Proc Am Soc Clin Oncol 2002, 21: 79. http://www.asco.org/

  11. Lassman AB, Rossi MR, Razier JR, et al.: Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium trials 01-03 and 00-01. Clin Cancer Res 2005, 11:7841–7850

    Article  PubMed  CAS  Google Scholar 

  12. Prados MD, Lamborn KR, Chang S, et al.: Phase I study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma. Neuroncology 2006, 8: 67–78http://www.asco.org/

    CAS  Google Scholar 

  13. Raizer JJ, Abrey LE, Wen P, et al.: A phase II trial of erlotinib (OSI-774) in patients (pts) with recurrent malignant gliomas (MG) not on EIAEDs [abstract]. Proc Am Soc Clin Oncol 2004, 22: 1502

    Google Scholar 

  14. Heimberger AB, Learn CA, Archer GE, et al.: Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (Iressa). Clin Cancer Res 2002, 8: 3496–3502

    PubMed  CAS  Google Scholar 

  15. Vogelbaum MA, Peereboom D, Stevens G, et al.: Phase II trial of the EGFR tyrosine kinase inhibitor erlotinib for single agent therapy of recurrent glioblastoma multiforme: interim results [abstract]. Proc Am Soc Clin Oncol 2004, 22: 1558. http://www.asco.org/

  16. Cloughesy T, Yung A, Vrendenberg J, et al.: Phase II study of erlotinib in recurrent GBM: molecular predictors of outcome [abstract]. Proc Am Soc Clin Oncol 2005; 23: 1507. http://www.asco.org/

  17. Prados M, Yung W, Wen, et al.: Phase I study of ZD1839 plus temozolomide in patients with malignant glioma. A study of the North American Brain Tumor Consortium [abstract]. Proc Am Soc Clin Oncol 2004, 22: 1504. http://www.asco.org/

  18. Lieberman FS, Cloughesy T, Fine H, et al.: NABTC phase I/II trial of ZD-1839 for recurrent malignant gliomas and unresectable meningiomas [abstract]. Proc Am Soc Clin Oncol 2004, 22: 1510. http://www.asco.org/

  19. Rich JN, Reardon DA, Peery T, et al.: Phase II trial of gefinitib in recurrent glioblastoma. J Clin Oncol 2004, 22: 133–142

    Article  PubMed  CAS  Google Scholar 

  20. Uhm JH, Ballman KV, Giannini C, et al.: Phase II study of ZD1839 in patients with newly diagnosed grade 4 astrocytoma [abstract]. Proc Am Soc Clin Oncol 2004, 22: 1505

    Google Scholar 

  21. Krishnan S, Brown P, Ballman K, et al.: Phase I trial of erlotinib with radiation therapy (RT) in patients with glioblastoma multiforme (GBM) [abstract]. Proc Am Soc Clin Oncol 2005, 23: 1513. http://asco.org/

  22. Van Den Bent MJ, Brandes A, Rampling R, et al.: Randomized phase II trial of erlotinib (E) versus temozolomide (TMZ) or BCNU in recurrent glioblastoma multiforme (GBM): EORTC 26034 [abstract]. Proc Am Soc Clin Oncol 2007, 25: 2005. http://asco.org/

  23. Lynch TJ, Bell DW, Sordella R, et al.: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350: 2129–2139http://www.asco.org/

    Article  PubMed  CAS  Google Scholar 

  24. Paez JG, Janne PA, Lee JC, et al.: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497–1500http://www.asco.org/

    Article  PubMed  CAS  Google Scholar 

  25. Marie Y, Carpentier AF, Omuro AM, et al.: EGFR tyrosine kinase domain mutations in human gliomas. Neurology 2005, 64: 1444–1445http://www.asco.org/

    PubMed  CAS  Google Scholar 

  26. Sarkaria JN, Yang L, Grogan PT, et al.: Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel. Mol Cancer Ther 2007, 6:1167–1174

    Article  PubMed  CAS  Google Scholar 

  27. ••Mellinghoff IK, Wang MY, Vivanco I, et al.: Molecular determinants of the response of glioblastoma to EGFR kinase inhibitors. N Engl J Med 2005, 353: 2012–2024http://www.asco.org/

    Article  PubMed  CAS  Google Scholar 

Identified EGFRvIII and PTEN status as a key predictor to erlotinib sensitivity

  1. Brewer CJ, Suh JH, Stevens GH, et al.: Phase II trial of erlotinib with temozolomide and concurrent radiation therapy in patients with newly-diagnosed glioblastoma multiforme [abstract]. Proc Am Soc Clin Oncol 2005, 23: 1567. http://asco.org/

  2. Chakravarti A, Berkey B, Robins HI, et al.: An update of phase II results from RTOG 0211: a phase I/II study of gefitinib with radiotherapy in newly diagnosed glioblastoma [abstract]. Proc Am Soc Clin Oncol 2006, 24: 1527. http://asco.org/

  3. Eller JL, Longo SL, Hicklin DJ, Canute GW: Activity of anti-epidermal growth factor receptor monoclonal antibody C225 against glioblastoma multiforme. Neurosurgery 2002, 51:1005–1013

    Article  PubMed  Google Scholar 

  4. Eller JL, Longo SL, Kyle MM, et al.: Anti-epidermal growth factor receptor monoclonal antibody cetuximab augments radiation effects in glioblastoma multiforme in vitro and in vivo. Neurosurgery 2005, 56:155–162

    PubMed  Google Scholar 

  5. Combs SE, Schulz-Ertner D, Roth W, et al.: In vitro responsiveness of glioma cell lines to multimodality treatment with radiotherapy, temozolomide, and epidermal growth factor receptor inhibition with cetuximab. Int J Radiat Oncol Biol Phys 2007, 68:873–882

    PubMed  CAS  Google Scholar 

  6. Sok JC, Coppelli FM, Thomas SM, et al.: Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res 2006, 12:5064–5073

    Article  PubMed  CAS  Google Scholar 

  7. Li D, Ji H, Zaghlul S, et al.: Therapeutic anti-EGFR antibody 806 generates responses in murine de novo EGFR mutant-dependent lung carcinomas. J Clin Invest 2007, 117:346–352

    Article  PubMed  CAS  Google Scholar 

  8. Crombet-Ramos T, Rak J, Perez R, Viloria-Petit A: Antiproliferative, antiangiogenic and proapoptotic activity of h-R3: a humanized anti-EGFR antibody. Int J Cancer 2002, 101:567–575

    Article  PubMed  CAS  Google Scholar 

  9. Sadones J, Chaskis C, Joosens EJ, et al.: A stratified phase II study of cetuximab for the treatment of recurrent glioblastoma multiforme: preliminary results [abstract]. Proc Am Soc Clin Oncol 2006, 24: 1558. http://asco.org/

  10. Combs SE, Heeger S, Haselmann R, et al.: Treatment of primary glioblastoma multiforme with cetuximab, radiotherapy and temozolomide (GERT) - phase I/II trial: study protocol. BMC Cancer 2006, 6:133

    Article  PubMed  CAS  Google Scholar 

  11. Scott AM, Lee FT, Tebbutt N, et al.: A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors. Proc Natl Acad Sci USA 2007, 104:4071–4076

    Article  PubMed  CAS  Google Scholar 

  12. Ramos TC, Figueredo J, Catala M, et al.: Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3. Cancer Biol Ther 2006, 5:375–379

    Article  PubMed  CAS  Google Scholar 

  13. Bode U, Buchen S, Warmuth-Metz M, et al.: Final report of a phase II trial of nimotuzumab in the treatment of refractory and relapsed high-grade gliomas in children and adolescents [abstract]. Proc Am Soc Clin Oncol 2007, 25:2006. http://asco.org/

  14. Heimberger AB, Crotty LE, Archer GE, et al.: Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. Clin Cancer Res 2003, 9:4247–4254

    PubMed  CAS  Google Scholar 

  15. Heimberger AB, Hussain SF, Aldape K, et al.: Tumor-specific peptide vaccination in newly-diagnosed patients with GBM [abstract]. Proc Am Soc Clin Oncol 2006, 24:2529

    Google Scholar 

  16. Sampson JH, Aldape KD, Gilbert MR, et al.: Temozolomide as a vaccine adjuvant in GBM [abstract]. Proc Am Soc Clin Oncol 2007, 25:2020. http://asco.org/

  17. Fan QW, Specht KM, Zhang C, et al.: Combinatorial efficacy achieved through two-point blockade within a signaling pathway—a chemical genetic approach. Cancer Res 2003, 63:8930–8938

    PubMed  CAS  Google Scholar 

  18. Nguyen TD, Lassman AB, Lis E, et al.: A pilot study to assess the tolerability and efficacy of RAD-001 (everolimus) with gefitinib in patients with recurrent glioblastoma multiforme (GBM) [abstract]. Proc Am Soc Clin Oncol 2006, 24:1507. http://asco.org/

  19. Robins HI, Wen PY, Chang SM, et al.: Phase I study of erlotinib and CCI-779 (temsirolimus) for patients with recurrent malignant gliomas (MG) (NABTC 04-02) [abstract]. Proc Am Soc Clin Oncol 2007, 25:2057. http://asco.org/

  20. Fan QW, Cheng SK, Nicolaides TP, et al.: A dual phosphoinositide-3-kinase α/ mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma. Cancer Res 2007, 67:7960–7965

    Article  PubMed  CAS  Google Scholar 

  21. Freemantle SJ, Liu Z, Feng Q, et al.: Cyclin degradation for cancer therapy and chemoprevention. J Cell Biochem 2007, 102:869–877

    Article  PubMed  CAS  Google Scholar 

  22. Dragnev KH, Petty WJ, Shah S, et al.: Bexarotene and erlotinib for aerodigestive tract cancer. J Clin Oncol 2005, 23: 8757–8764

    Article  PubMed  CAS  Google Scholar 

  23. Chakravarti A, Delaney MA, Noll E, et al.: Prognostic and pathologic significance of quantitative protein expression profiling in human gliomas. Clin Cancer Res 2001, 7:2387–2395

    PubMed  CAS  Google Scholar 

  24. Yung WK, Kyritsis AP, Gleason MJ, Levin VA. Treatment of recurrent malignant gliomas with high-dose 13-cis-retinoic acid. Clin Cancer Res 1996, 2:1931–1935

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Section on Hematology and Oncology, Wake Forest University Baptist Medical Center, Medical Center Blvd, Winston Salem, NC, 27157, USA

    Will R. Voelzke MD, W. Jeffery Petty MD & Glenn J. Lesser MD

Authors
  1. Will R. Voelzke MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. W. Jeffery Petty MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Glenn J. Lesser MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Glenn J. Lesser MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Voelzke, W.R., Petty, W.J. & Lesser, G.J. Targeting the Epidermal Growth Factor Receptor in High-Grade Astrocytomas. Curr. Treat. Options in Oncol. 9, 23–31 (2008). https://doi.org/10.1007/s11864-008-0053-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-008-0053-5

Keywords

Search

Navigation